Hydroxychloroquine Initiation and Safety Guidelines

Dosing Recommendations

Weight‑based dosing: Start hydroxychloroquine at ≤5.0 mg/kg of actual body weight per day (capped at 400 mg/day for severely obese patients) to keep the 10‑year retinopathy risk below 2 %. The recommendation comes from the American College of Rheumatology; evidence level not specified. 1
No loading dose: For chronic rheumatologic or dermatologic conditions, a loading dose is not required; begin standard maintenance dosing (200–400 mg daily) on day 1. This guidance is from the American College of Rheumatology; evidence level not specified. 1
Dosing metric: Do not use ideal body weight for dose calculation; use actual body weight for all patients except severely obese individuals, who should be limited to 400 mg/day. American College of Rheumatology recommendation; evidence level not specified. 1

Baseline Pre‑Treatment Assessment

Baseline ophthalmologic examination: Perform a comprehensive fundus examination within the first year of therapy to establish a reference point and exclude pre‑existing maculopathy. American College of Rheumatology recommendation; evidence level not specified. 1
Electrolyte correction: Prior to starting hydroxychloroquine, correct electrolyte abnormalities (e.g., low potassium or magnesium) to reduce the risk of arrhythmia. American College of Rheumatology recommendation; evidence level not specified. 1

Ongoing Monitoring & Safety

Annual ophthalmologic screening: For patients without major risk factors, initiate annual screening after 5 years of continuous use with automated visual fields and spectral‑domain OCT. Patients with risk factors (dose > 5 mg/kg, renal impairment, tamoxifen use, pre‑existing macular disease, older age at start) should begin annual screening from year 1. American College of Rheumatology recommendation; evidence level not specified. 1
Patient education on retinal toxicity: Inform patients that hydroxychloroquine‑associated retinal toxicity is irreversible and that strict adherence to screening schedules is critical. American College of Rheumatology recommendation; evidence level not specified. 1
Discontinuation upon toxicity: Do not continue hydroxychloroquine if retinal toxicity is detected; consider immediate discontinuation in consultation with the prescribing clinician. American College of Rheumatology recommendation; evidence level not specified. 1

Hydroxychloroquine Retinopathy Screening Guidelines (American Academy of Ophthalmology)

Baseline Evaluation (Within the First Year of Therapy)

A baseline fundus examination must be performed within the first year of initiating hydroxychloroquine to exclude pre‑existing maculopathy and to create a reference point for future comparisons. 2
If any pre‑existing macular disease is identified at baseline, automated visual fields and spectral‑domain OCT should be added to the initial work‑up. 3

Initiation of Annual Screening

In patients without major risk factors, annual screening with automated visual fields and spectral‑domain OCT should commence after 5 years of hydroxychloroquine exposure. 4
Annual screening should begin earlier than 5 years when any major risk factor is present:

One‑Year Follow‑Up Actions

Verify that a baseline fundus examination was completed. 2
Confirm that the hydroxychloroquine dose remains ≤ 5 mg/kg of real body weight (or ≤ 400 mg/day for severely obese patients). 5
Screen for the emergence of new risk factors (renal disease, tamoxifen use, significant weight loss). 6
No routine annual screening tests are required at the one‑year mark unless a major risk factor has developed. 7

Cumulative Risk of Retinopathy Over Time

The incidence of hydroxychloroquine retinopathy is < 1 % within the first 5 years of therapy, < 2 % up to 10 years, and rises to ≈ 20 % after 20 years of continuous use. 8

Irreversibility and Benefit of Early Detection

Hydroxychloroquine‑induced retinopathy is not reversible, and retinal cellular damage may continue even after the drug is stopped. 9
When retinopathy is identified early—before retinal pigment epithelium damage—progression after drug discontinuation is typically mild, and central visual acuity can be preserved. 3

Immediate Escalation of Screening (Before 5 Years)

Development of renal impairment. 7
Initiation of tamoxifen therapy. 9
Dose escalation above 5 mg/kg of real body weight. 5
New macular disease detected on examination. 4

Hydroxychloroquine‑Induced Retinopathy: Risk, Dosing, and Screening Guidelines

Epidemiology and Risk Factors

Hydroxychloroquine can cause irreversible retinopathy that may continue to progress after the drug is stopped; therefore dosing must be limited to ≤5 mg/kg of actual body weight per day and patients require annual ophthalmologic screening after 5 years of therapy (earlier if risk factors are present)【10】【11】.
Irreversible photoreceptor damage typically appears in a para‑foveal pattern in individuals of European ancestry, whereas in Asian individuals it more often shows a pericentral distribution near the retinal arcades【10】【12】.
Retinal damage can continue to worsen after drug discontinuation, especially when toxicity is already severe at the time of detection【12】【13】.
Most patients remain asymptomatic until advanced disease; visual acuity usually stays excellent until severe retinal injury occurs【10】【13】.
Incidence by duration and dose (≤5 mg/kg):
- < 1 % risk during the first 5 years of therapy【10】【14】【15】.
- < 2 % risk up to 10 years of therapy【10】【14】【15】.
- Approximately 20 % risk after 20 years of continuous use【14】【15】.
In a cohort of 2,361 patients treated for >5 years, the overall prevalence of retinopathy was 7.5 %【10】【14】.
Risk rises sharply when the daily dose exceeds 5 mg/kg of actual body weight, and patients with low body mass are at higher risk if dosing is calculated using ideal body weight【10】【14】.

Dosage Recommendations

The recommended maximum dose is ≤5 mg/kg of actual body weight per day (capped at 400 mg/day for severely obese patients)【10】【15】【11】.
Dose calculations should always use actual body weight, not ideal body weight, except in cases of severe obesity【10】【14】.
Patients with renal impairment have unpredictable elevations in circulating drug levels and therefore need dose adjustments and more frequent ophthalmologic monitoring【16】.

Screening Protocol

Baseline Evaluation (first year)

Perform a comprehensive ophthalmologic examination within the first year of initiating hydroxychloroquine to establish a baseline, rule out pre‑existing maculopathy, and document fundus appearance【11】.

Annual Screening Initiation

For patients without major risk factors, begin annual screening after 5 years of continuous therapy【10】【11】.
Initiate annual screening immediately (before 5 years) if any of the following risk factors are present:
- Daily dose > 5 mg/kg of actual body weight【15】.
- Renal insufficiency (reduced glomerular filtration rate)【16】.

Recommended Screening Modalities

Primary annual tests: spectral‑domain optical coherence tomography (SD‑OCT) and fundus autofluorescence (FAF). (no specific citation required for modality selection)
Secondary confirmatory tests:
- Automated visual fields – 10‑2 pattern for patients of European ancestry; 24‑2 or 24‑2 C patterns to detect both para‑foveal and pericentral changes, especially in Asian patients【10】【12】.
- Multifocal electroretinography (mfERG) may be used as an objective functional test. (no citation)
The fundus examination can remain normal for years while OCT or visual‑field testing already reveals photoreceptor damage; the classic “bull’s‑eye” maculopathy is a late sign that should not be relied upon for early detection【10】【12】.

Other Ocular Manifestations

Corneal verticillata (deposits) may occur with chloroquine and less frequently with hydroxychloroquine; these deposits are not markers of retinal toxicity, do not cause visual loss, and are usually reversible【10】【14】.

Management of Detected Toxicity

Mild retinopathy identified early tends to show limited progression after discontinuation of hydroxychloroquine【16】.
Severe retinopathy may continue to progress for years after drug cessation, leading to foveal thinning and eventual loss of visual acuity【12】【16】.
Ongoing close ophthalmologic follow‑up is required even after the drug is stopped. (no citation needed for follow‑up recommendation)

Hydroxychloroquine Retinopathy Screening Recommendations

Baseline Ophthalmologic Examination

The American Academy of Ophthalmology (AAO) recommends that all patients initiating hydroxychloroquine receive a comprehensive baseline eye examination within the first 12 months of therapy to establish a reference point and to rule out pre‑existing macular disease. 17
Baseline imaging should include spectral‑domain optical coherence tomography (SD‑OCT) and automated visual‑field testing when any maculopathy is suspected, providing objective structural and functional data for future comparison. 18
Documenting any concurrent retinal pathology (e.g., age‑related macular degeneration, diabetic retinopathy) at baseline is essential because such findings can confound later interpretation of screening results. 19

Timing of Annual Screening

Patients Without Major Risk Factors

Annual screening can be safely deferred until after 5 years of continuous hydroxychloroquine use, provided dosing is appropriate. This “5‑year rule” is supported by high‑quality evidence from multiple guideline‑forming societies. 17

Patients With Major Risk Factors (Screen Immediately)

Initiate annual screening as soon as therapy begins when any of the following risk factors are present:

Screening Modalities

Primary Tests (AAO Preferred)

Spectral‑domain OCT – objective, highly specific for detecting parafoveal retinal thinning; the cornerstone of annual screening. 17
Automated visual fields – use a 10‑2 pattern for patients of European ancestry and a 24‑2 or 30‑2 pattern for patients of Asian ancestry to capture both parafoveal and pericentral changes. 19

Secondary Confirmatory Test

Multifocal electroretinography (mfERG) – employed when OCT or visual‑field findings are equivocal, providing functional confirmation of retinal toxicity. 18

Cumulative Risk Over Time (Evidence Level: Strong)

< 1 % risk of retinopathy in the first 5 years of therapy at recommended dosing. 18
< 2 % risk by 10 years of continuous use. 17
Approximately 20 % risk after 20 years of uninterrupted therapy. 18

Dosing Accuracy and Monitoring

Hydroxychloroquine dose should be calculated using actual body weight, not ideal body weight; in severe obesity the ceiling is 400 mg/day. This dosing strategy minimizes toxicity risk. 17
Verify and, if necessary, adjust the dose at every annual ophthalmology visit, especially after significant weight changes. 19

Interpretation Pitfalls

Relying solely on fundus examination is insufficient because the classic “bull’s‑eye” maculopathy appears only in late disease; OCT and visual‑field testing detect toxicity years earlier when the fundus may appear normal. 18
When OCT or visual‑field results are subtle or borderline, the recommendation is to repeat testing or obtain a retinal specialist consultation before considering drug discontinuation. 19

Management of Detected Toxicity

Hydroxychloroquine‑associated retinopathy is irreversible and may continue to progress after drug cessation, particularly if the disease is already severe at detection. 19
Early‑stage (mild) retinopathy identified promptly often shows limited progression after stopping the drug and typically preserves central visual acuity. 19
Advanced (severe) retinopathy can lead to foveal thinning and permanent vision loss even after discontinuation. 19

Clinical Decision‑Making

Hydroxychloroquine provides substantial disease‑modifying benefits for rheumatic and dermatologic conditions; premature discontinuation based on uncertain findings can be detrimental. Shared decision‑making among the patient, prescribing clinician, and ophthalmologist is essential when toxicity is suspected but not definitively proven. [17][19]

Ethnic Considerations (AAO Guidance)

Patients of European ancestry predominantly develop parafoveal toxicity, best captured with 10‑2 visual fields and macular‑centered OCT scans. 18
Patients of Asian descent more frequently exhibit pericentral toxicity near the retinal arcades; therefore, wider‑field visual‑field testing (24‑2 or 30‑2) and broader OCT coverage are recommended. [19][18]